Eledon Pharmaceuticals, Inc.
ELDN
$3.88
-$0.02-0.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.63% | -7.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.66% | -22.90% | |||
| Operating Income | -12.66% | 22.90% | |||
| Income Before Tax | 40.36% | -55.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 40.16% | -55.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.16% | -55.66% | |||
| EBIT | -12.66% | 22.90% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 51.84% | -55.36% | |||
| Normalized Basic EPS | 51.98% | -55.34% | |||
| EPS Diluted | 51.84% | -55.36% | |||
| Normalized Diluted EPS | 51.98% | -55.34% | |||
| Average Basic Shares Outstanding | 24.26% | 0.15% | |||
| Average Diluted Shares Outstanding | 24.26% | 0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||